The combination of better data and more powerful computing is helping researchers reinvent the process of discovering new drugs. Within 5-10 years, we’ll likely see a huge wave of new medicines that were either discovered or designed using AI—drugs that will finally help us get control of our most stubborn health problems, from cancer to cardiovascular disease to obesity and metabolic disorders to neurodegenerative diseases. And the biotech startups that will do most to contribute are the ones that have both proprietary data, and original ways to use AI to sift through that data. Harry's guests this week are from a startup called Pangea Bio that’s working hard on both. As Pangea's co-founder and COO, John Boghossian, and its president of AI, Sona Chandra, explain, the company specializes in gathering data from the natural world, especially data about compounds manufactured inside the cells of plants and fungi. They narrow down the possibilities by working with indigenous cultures to find the plants or mushrooms that people have already been using for centuries in traditional medicine. They've also built three separate computational platforms that filter through all that data, to single out the small molecules that have the biggest effects in the human body, especially the central nervous system.